Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.
Document Type
Article
Publication Date
5-1-2017
Abstract
A 17-year-old girl with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) with persistent minimal residual disease (MRD) who underwent standard chemotherapy was found to have a BCR-ABL1-like gene expression pattern. Genome sequencing revealed a JAK2 mutation not previously described in BCP-ALL and a potential therapeutic target. Due to concern for an on-therapy relapse, the JAK2 inhibitor ruxolitinib was incorporated into a modified chemotherapy backbone to achieve complete remission prior to stem cell transplant. Treatment was well tolerated and she had undetectable MRD prior to a matched allogeneic stem cell transplant and remained in remission at day +100.
Publication Title
Pediatric blood & cancer
ISSN
1545-5017
Volume
64
Issue
5
Recommended Citation
Mayfield, Jodi R; David R Czuchlewski; James M Gale; Ksenia Matlawska-Wasowska; Mohammad A Vasef; Christian Nickl; Gavin Pickett; Scott A Ness; and Stuart S Winter.
"Integration of ruxolitinib into dose-intensified therapy targeted against a novel JAK2 F694L mutation in B-precursor acute lymphoblastic leukemia.."
Pediatric blood & cancer
